Full-Time

Sales Representative

Deadline 5/29/26
LeMaitre

LeMaitre

501-1,000 employees

Global provider of vascular surgery devices.

No salary listed

Philadelphia, PA, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree (B.A. or B.S.) from four year college or university; or one to two years related experience and/or training; or equivalent combination of education and experience.
  • Three to Five years sales experience (medical devices preferred) or at least two years of related clinical experience in a hospital setting.
  • Proficiency with Internet, MS Word, MS Excel and MS Outlook
  • Travel requirement (25-50%)
Responsibilities
  • Achieve monthly, quarterly and annual sales objectives
  • Propose pricing for customer quotes and offers
  • Acquire product knowledge to detail and sell company product portfolio
  • Attend and learn how to support company products use in the operating theatre
  • Develop and maintain relationships with all hospital purchasing contacts through regular visits
  • Attend trade shows as required
  • Build relationships with Key Opinion Leaders within corresponding areas of responsibility
  • Manage the sales reporting and the rolling forecast
  • Develop and Maintain company customer relations management software program on a daily basis

LeMaitre develops medical devices for vascular surgery, focusing on peripheral vascular disease. Its main product, the LeMaitre Valvulotome, lets surgeons cut valves in peripheral veins without direct vision, improving treatment of lower-extremity arterial disease and helping to save legs; the portfolio also includes aortic grafts, vascular allografts, occlusion catheters, AV access systems, and collagen grafts. The devices are developed in-house and sold directly to hospitals, clinics, and vascular centers or via regional distributors, enabling surgeons to perform complex procedures more efficiently. By specializing in vascular devices with a global reach across 90 countries and a steady stream of R&D, LeMaitre aims to improve vascular treatment outcomes and broaden access to high-quality tools.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1983

Simplify Jobs

Simplify's Take

What believers are saying

  • Gross margin expanded 350 basis points to 72.7% driving 47% operating income growth.
  • International expansion targeting $10 million Artegraft sales via new country approvals.
  • All three regions posted record Q1 2026 sales: EMEA +20%, APAC +18%, Americas +7%.

What critics are saying

  • Artegraft regulatory filing delayed beyond H2 2026, stalling $10 million international sales target.
  • Intuitive Surgical's 23% revenue growth outpaces LeMaitre's 11-12%, capturing hospital budgets.
  • Stock trading at 328% premium to fair value triggers valuation compression risk.

What makes LeMaitre unique

  • Specialized vascular device portfolio across 25+ categories targeting niche surgeon needs.
  • Direct sales force and established relationships in 31 countries with 90+ country distribution.
  • Artegraft acquisition established largest product line with 36% Q1 2026 growth trajectory.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Employee Referral Bonus

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

Commuter Benefits

Employee Discounts

Company Social Events

Company News

Yahoo Finance
Mar 28th, 2026
LeMaitre Vascular senior VP sells $285K in stock as shares surge 30%

LeMaitre Vascular senior vice president of operations Trent Kamke sold 2,625 shares of common stock for approximately $285,000 on 11 March 2026, according to an SEC Form 4 filing. The transaction involved exercising fully vested stock options that were immediately converted and sold as common stock. The sale represented 28.22% of Kamke's pre-sale direct holdings, matching the median percentage of holdings traded per sale in his recent activity since December 2024. Following the transaction, Kamke's direct common stock holdings decreased to 6,677 shares, valued at approximately $722,000. LeMaitre Vascular manufactures medical devices and implants for treating peripheral vascular disease. The company reported $249.6 million in trailing twelve-month revenue and $57.7 million in net income, with shares up 30% over one year.

Yahoo Finance
Feb 26th, 2026
LeMaitre shares jump 16.8% on strong Q4 results, 2026 EPS guidance of $2.91 beats expectations

LeMaitre Vascular shares jumped 16.8% after the medical device company reported fourth-quarter 2025 results that exceeded expectations. Revenue reached $64.45 million, up 15.7% year-on-year, whilst earnings per share rose to $0.68 from $0.49 in the prior year's quarter. The company's operating margin expanded to 29.2% from 23.1% a year earlier. LeMaitre provided first-quarter revenue guidance above consensus and forecast full-year 2026 GAAP EPS of $2.91 at the midpoint, surpassing market predictions. The stock has risen 36.4% since the beginning of the year, reaching a new 52-week high of $109.39 per share. Investors who purchased shares five years ago have seen their investment more than double in value.

The Associated Press
Feb 25th, 2026
LeMaitre Vascular posts Q4 sales of $64.5M, raises dividend 25% and authorises $100M share buyback

LeMaitre Vascular reported Q4 2025 sales of $64.5 million, up 16% year-over-year, with organic growth of 15%. The medical device company's operating income surged 47% to $18.8 million, whilst diluted earnings per share rose 39% to $0.68. Growth was driven by grafts (up 27%), valvulotomes (up 20%) and carotid shunts (up 18%). Regionally, EMEA sales increased 29%, APAC 20% and the Americas 10%. Gross margin expanded 240 basis points to 71.7% due to higher selling prices and manufacturing efficiencies. The company increased its quarterly dividend by 25% to $0.25 per share and authorised a $100 million share buyback programme. For 2026, LeMaitre guided sales of $280 million (up 12%) and adjusted operating income of $77.8 million (up 21%).

Stock Titan
May 5th, 2025
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

LeMaitre to present at the Bank of America Securities 2025 Healthcare Conference.

BioSpace
Mar 20th, 2025
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

Mr. Pellegrino joined LeMaitre Vascular as their Executive Vice President, Finance, in 2005.